DOCSLIB.ORG

Modification of the Prosegment in Understanding Its Role in the Folding and Function of PMII

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modification of the Prosegment in Understanding Its Role in the Folding and Function of PMII Modification of the Prosegment in Understanding its Role in the Folding and Function of PMII by Ahmad Haniff Jaafar A Thesis Presented to The University of Guelph In partial fulfillment of requirements for the degree of Doctor of Philosophy in Food Science Guelph, Ontario, Canada © Ahmad Haniff Jaafar, August, 2014 ABSTRACT MODIFICATION OF THE PROSEGMENT IN UNDERSTANDING ITS ROLE IN THE FOLDING AND FUNCTION OF PMII Ahmad Haniff Jaafar Advisor: University of Guelph, 2014 Professor R.Y. Yada This thesis explores the folding and activation of plasmepsin II (PMII) and the role of its prosegment (PS) on structure – function. Three different constructs of PMII were designed with PSs of varying lengths: extended PSPMII with a 60 residue PS, truncated PSPMII with a 48 residue PS, and NoProPMII with no PS. Extended and truncated PSPMII produced mature enzyme with similar conformation. NoProPMII mature, however, showed improper folding as indicated by low thermal stability, a more solvent-exposed conformation, an 11-fold reduction in the activity assay, and a lower pepstatin-A requirement for complete inhibition. In addition, the PS length was discovered to affect the activation of PMII. Extended PSPMII produced mature enzyme with an extra two PS residues (+2 PMII mature) whereas truncated PSPMII produced mature enzyme with an extra 12 PS residues (+12 PMII mature). The role of a PS in PMII folding was further investigated by conducting folding kinetic studies on PMII. It was found that the native PMII (Np) did not fold at the lowest free energy, but was kinetically stabilized. Upon unfolding, Np formed a thermodynamically stable, yet inactive refolded state (Rp). Np was characterized to have a slow rate of unfolding and folding, as indicated by large free energy barriers to unfold and fold of 24.50 and 25.12 kcal/mol, respectively. In the presence of the extended PS (60 residues), the energy landscape was shifted and the activation energy barrier was lowered to 12.37 kcal/mol, which enhanced the folding rate by approximately 18,550 times. To elucidate the effect of PS residue length on PMII folding, structural analysis and in silico simulation were conducted on the two zymogens of PMII: extended PSPMII and truncated PSPMII. Both zymogens appeared to be in a more solvent-exposed conformation as compared to their mature forms. Due to the oppositely charged residues between the main protein body and the PS, it appeared that the interactions between both structures were driven by electrostatic forces with 27 and 34 interactions (H-bonds and salt-bridges) measured between the main PMII body and truncated and extended PS, respectively. ACKNOWLEDGEMENTS It gives me great honour to acknowledge herein Prof. Rickey Yada for his intellectual guidance and unceasing support rendered towards me during my Ph.D. candidature at University of Guelph. My time at Guelph has been a truly remarkable journey of self exploration and knowledge enrichment best indicated by the completion of my studies, and presentation of this thesis thereafter. Million thanks also go to my Advisory Committees Prof.Yoshinori Mine, Prof. George Harauz and Prof. Alejandro Marangoni who have equally contributed in making my success achievable. My deepest and most sincere gratitude is thus conveyed to my family and parents. Their love and compassion have always ignited the passion in me to strive and persevere in order to make it to the finishing line. As such, my success is as much as it is theirs. Great thanks to my colleagues, especially all my lab mates Huogen, Brian, Yasumi, Dref, Derek, Charity, Brenna and Reena for their help during my time in Guelph. My appreciation is also extended to Mary Anne Smith for her expert editing throughout my entire thesis. And last but never least, to my employer, Universiti Putra Malaysia (UPM), and my sponsor, Malaysian Ministry of Education (MOE), I am most grateful for and thus fully acknowledge the chance and opportunity given to me. My Ph.D. would not be completed without the financial support and endorsement from both parties. THANK YOU. iv TABLE OF CONTENTS ABSTRACT ............................................................................................................................................ ii ACKNOWLEDGEMENTS ................................................................................................................... iv TABLE OF CONTENTS ........................................................................................................................ v LIST OF TABLES ............................................................................................................................... viii LIST OF FIGURES ............................................................................................................................... ix LIST OF ABBREVIATIONS ................................................................................................................ xi CHAPTER 1 Introduction and literature review ................................................................. 1 1.1 Introduction ................................................................................................................................ 1 1.2 Literature Review ....................................................................................................................... 5 1.2.1 The family of APs ................................................................................................................. 5 1.2.2 General structure and mechanism of APs ............................................................................. 7 1.2.3 Multifunctional PS in APs ................................................................................................... 10 1.2.4 Prosegment catalyst folding ................................................................................................ 12 1.2.5 Prosegment catalyzed folding in APs .................................................................................. 13 1.2.6 Malarial APs ........................................................................................................................ 14 1.2.7 Plasmepsin II ....................................................................................................................... 15 1.2.8 Expression of PMII ............................................................................................................. 16 1.2.9 Unique characteristic of the PMII PS .................................................................................. 17 CHAPTER 2 Characterization of PMII with various lengths of prosegment ................. 19 2.1 Introduction .............................................................................................................................. 19 2.2 Materials and Methods ............................................................................................................ 20 2.2.1 Materials .............................................................................................................................. 20 2.2.2 Generation of PMII expression constructs .......................................................................... 20 2.2.3 Expression and purification of PMII constructs .................................................................. 22 2.2.4 Purification of PMII constructs ........................................................................................... 22 2.2.4.1 Extended PSPMII and truncated PSPMII ................................................................. 23 2.2.4.2 NoProPMII ................................................................................................................ 24 2.2.5 Protein concentration determination of PMII constructs and mature enzymes ................... 24 2.2.6 Optimum pH of activity and stability of PMII mature enzymes ......................................... 25 2.2.7 Structural characteristic analysis of PMII mature enzymes ................................................ 26 2.2.7.1 Far-UV circular dichroism spectroscopy.................................................................... 26 2.2.7.2 Intrinsic fluorescence spectroscopy ............................................................................ 26 2.2.8 Thermostability analysis using differential scanning calorimetry ....................................... 26 2.2.9 Kinetic parameters of PMII mature enzymes ...................................................................... 27 2.2.10 Active enzyme comparison of PMII mature enzymes ...................................................... 27 2.2.11 Structural prediction of +2 PMII and +12 PMII mature enzymes ..................................... 28 2.2.12 Statistical Analysis ............................................................................................................ 28 2.3 Results and Discussion ............................................................................................................. 28 2.3.1 Construction and soluble expression of PMII constructs .................................................... 28 2.3.2 Purification of PMII constructs ........................................................................................... 35 2.3.3 Activation to +2 PMII, +12 PMII, and NoProPMII mature enzymes ................................. 43 2.3.4 Optimum pH of activity and stability of PMII mature enzymes ......................................... 45 2.3.5 Structural characteristics of PMII mature enzymes............................................................
Load more

Recommended publications
  • Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
    Journal of the American Heart Association ORIGINAL RESEARCH Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals Joonatan Palmu , MD; Aaro Salosensaari , MSc; Aki S. Havulinna , DSc (Tech); Susan Cheng , MD, MPH; Michael Inouye, PhD; Mohit Jain, MD, PhD; Rodolfo A. Salido , BSc; Karenina Sanders , BSc; Caitriona Brennan, BSc; Gregory C. Humphrey, BSc; Jon G. Sanders , PhD; Erkki Vartiainen , MD, PhD; Tiina Laatikainen , MD, PhD; Pekka Jousilahti, MD, PhD; Veikko Salomaa , MD, PhD; Rob Knight , PhD; Leo Lahti , DSc (Tech); Teemu J. Niiranen , MD, PhD BACKGROUND: Several small-scale animal studies have suggested that gut microbiota and blood pressure (BP) are linked. However, results from human studies remain scarce and conflicting. We wanted to elucidate the multivariable-adjusted as- sociation between gut metagenome and BP in a large, representative, well-phenotyped population sample. We performed a focused analysis to examine the previously reported inverse associations between sodium intake and Lactobacillus abun- dance and between Lactobacillus abundance and BP. METHODS AND RESULTS: We studied a population sample of 6953 Finns aged 25 to 74 years (mean age, 49.2±12.9 years; 54.9% women). The participants underwent a health examination, which included BP measurement, stool collection, and 24-hour urine sampling (N=829). Gut microbiota was analyzed using shallow shotgun metagenome sequencing. In age- and sex-adjusted models, the α (within-sample) and β (between-sample) diversities of taxonomic composition were strongly re- lated to BP indexes (P<0.001 for most). In multivariable-adjusted models, β diversity was only associated with diastolic BP (P=0.032).
    [Show full text]
  • Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 2020 Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens LU LU ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-513-1148-7 UPPSALA urn:nbn:se:uu:diva-435815 2021 Dissertation presented at Uppsala University to be publicly examined in Room A1:111a, BMC, Husargatan 3, Uppsala, Friday, 16 April 2021 at 13:15 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Christian Cambillau. Abstract Lu, L. 2021. Structural and Biochemical Characterizations of Three Potential Drug Targets from Pathogens. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 2020. 91 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-1148-7. As antibiotic resistance of various pathogens emerged globally, the need for new effective drugs with novel modes of action became urgent. In this thesis, we focus on infectious diseases, e.g. tuberculosis, malaria, and nosocomial infections, and the corresponding causative pathogens, Mycobacterium tuberculosis, Plasmodium falciparum, and the Gram-negative ESKAPE pathogens that underlie so many healthcare-acquired diseases. Following the same- target-other-pathogen (STOP) strategy, we attempted to comprehensively explore the properties of three promising drug targets. Signal peptidase I (SPase I), existing both in Gram-negative and Gram-positive bacteria, as well as in parasites, is vital for cell viability, due to its critical role in signal peptide cleavage, thus, protein maturation, and secreted protein transport. Three factors, comprising essentiality, a unique mode of action, and easy accessibility, make it an attractive drug target.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Proteolytic Enzymes in Grass Pollen and Their Relationship to Allergenic Proteins
    Proteolytic Enzymes in Grass Pollen and their Relationship to Allergenic Proteins By Rohit G. Saldanha A thesis submitted in fulfilment of the requirements for the degree of Masters by Research Faculty of Medicine The University of New South Wales March 2005 TABLE OF CONTENTS TABLE OF CONTENTS 1 LIST OF FIGURES 6 LIST OF TABLES 8 LIST OF TABLES 8 ABBREVIATIONS 8 ACKNOWLEDGEMENTS 11 PUBLISHED WORK FROM THIS THESIS 12 ABSTRACT 13 1. ASTHMA AND SENSITISATION IN ALLERGIC DISEASES 14 1.1 Defining Asthma and its Clinical Presentation 14 1.2 Inflammatory Responses in Asthma 15 1.2.1 The Early Phase Response 15 1.2.2 The Late Phase Reaction 16 1.3 Effects of Airway Inflammation 16 1.3.1 Respiratory Epithelium 16 1.3.2 Airway Remodelling 17 1.4 Classification of Asthma 18 1.4.1 Extrinsic Asthma 19 1.4.2 Intrinsic Asthma 19 1.5 Prevalence of Asthma 20 1.6 Immunological Sensitisation 22 1.7 Antigen Presentation and development of T cell Responses. 22 1.8 Factors Influencing T cell Activation Responses 25 1.8.1 Co-Stimulatory Interactions 25 1.8.2 Cognate Cellular Interactions 26 1.8.3 Soluble Pro-inflammatory Factors 26 1.9 Intracellular Signalling Mechanisms Regulating T cell Differentiation 30 2 POLLEN ALLERGENS AND THEIR RELATIONSHIP TO PROTEOLYTIC ENZYMES 33 1 2.1 The Role of Pollen Allergens in Asthma 33 2.2 Environmental Factors influencing Pollen Exposure 33 2.3 Classification of Pollen Sources 35 2.3.1 Taxonomy of Pollen Sources 35 2.3.2 Cross-Reactivity between different Pollen Allergens 40 2.4 Classification of Pollen Allergens 41 2.4.1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • New Retroviral-Like Membrane-Associated Aspartic Proteases From
    Novas proteases aspárticas membranares do tipo retroviral de rickettsiae: caracterização bioquímica e determinação de especificidade New retroviral-Iike membrane-associated aspartic proteases from rickettsiae: biochemical characterization and specificity profiling Tese de Doutoramento apresentada à Universidade de Coimbra para obtenção do grau de Doutor em Bioquímica (especialidade de Tecnologia Bioquímica). Doctoral thesis in the scientific area of Biochemistry (specialty Biochemistry Technology) presented to the University of Coimbra. Rui Gonçalo Batista Mamede da Cruz Coimbra - 2014 Department of Life Sciences University of Coimbra UNIVERSIDADE DE COIMBRA Front cover image illustrates Rickettsia cells (in green) invading mammalian host cells. Publishing rights were granted by Michael Taylor, the original author of the image. Agradecimentos / Acknowledgments A conclusão desta etapa não teria sido possível sem o apoio incondicional da família, amigos, orientadores, colegas e de todos aqueles que foram cruzando o meu caminho e deixando o seu contributo, em particular nos últimos quatro anos que conduziram a esta dissertação. Gostaria por isso de lhes deixar algumas palavras de profundo e sincero agradecimento. Em primeiro lugar, gostaria de agradecer à Doutora Isaura Simões e ao Professor Carlos Faro, por me terem acolhido e proporcionado as excepcionais condições para a realização deste trabalho. Em especial à Doutora Isaura Simões, expresso a minha profunda gratidão pela orientação, rigor, sentido crítico e paixão com que encara a ciência. Agradeço-lhe por acreditar em mim e por me fazer ir sempre mais além. Um agradecimento muito especial a todos aqueles que fazem e fizeram parte do laboratório de Biotecnologia de Molecular do Biocant, pelo seu contributo no meu crescimento científico, profissional e pessoal.
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Identification of Inhibitors of the Transmembrane Protease Flak Of
    ORIGINAL RESEARCH Identification of inhibitors of the transmembrane protease FlaK of Methanococcus maripaludis Ina Coburger1, Yvonne Schaub1, Dirk Roeser1, Kornelia Hardes2, Patrick Maeder2, Nina Klee2, Torsten Steinmetzer2, Diana Imhof3, Wibke E. Diederich2 & Manuel E. Than1 1Leibniz Institute on Aging (FLI), Protein Crystallography Group, Beutenbergstr. 11, Jena 07745, Germany 2Department of Pharmaceutical Chemistry, Philipps University Marburg, Marbacher Weg 6, Marburg 35032, Germany 3Institute of Pharmacy, Pharmaceutical Chemistry I, University of Bonn, Brühler Str. 7, Bonn 53119, Germany Keywords Abstract Gel-shift protease assay, I-CLiP, inhibitors, membrane proteins, TFPP. GxGD- type intramembrane cleaving proteases (I-CLiPs) form a family of proteolytic enzymes that feature an aspartate- based catalytic mechanism. Yet, Correspondence they structurally and functionally largely differ from the classical pepsin-like Manuel E. Than, Leibniz Institute on Aging aspartic proteases. Among them are the archaeal enzyme FlaK, processing its (FLI), Beutenbergstr. 11, 07745 Jena, substrate FlaB2 during the formation of flagella andγ -secretase, which is cen- Germany. trally involved in the etiology of the neurodegenerative Alzheimer’s disease. We Tel: +49-3641-656170; Fax: +49-3641-656335; E-mail: [email protected] developed an optimized activity assay for FlaK and based on screening of a small in- house library and chemical synthesis, we identified compound 9 as the Funding Information first inhibitor of this enzyme. Our results show that this intramembrane protease No funding information provided. differs from classical pepsin- like aspartic proteases and give insights into the substrate recognition of this enzyme. By providing the needed tools to further Received: 12 November 2015; Revised: 23 study the enzymatic cycle of FlaK, our results also enable further studies towards February 2016; Accepted: 7 March 2016 a functional understanding of other GxGD- type I- CLiPs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]